加载中
NYSEHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$12.82
+US$0.34 · +2.72%
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.
收盘时
US$12.82
+US$0.34 · +2.72%
盘后
US$12.82
US$0.00 · 0.00%
10月12日 17:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.
日内区间
当前US$12.82
52周区间
当前US$12.82
盘中时间采用ET。市场数据可能有所延迟。
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.
日内区间
当前US$12.82
52周区间
当前US$12.82
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（INR） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 3534.72亿 INR | 3255.35亿 INR | 2791.64亿 INR | 2458.79亿 INR | 2143.91亿 INR |
| 销货成本 | 1669.53亿 INR | 1351.07亿 INR | 1155.57亿 INR | 1065.36亿 INR | 1005.51亿 INR |
| 毛利 | 1865.19亿 INR | 1904.28亿 INR | 1636.07亿 INR | 1393.43亿 INR | 1138.4亿 INR |
| 研究与开发 | 253.14亿 INR | 273.8亿 INR | 228.73亿 INR | 193.81亿 INR | 174.82亿 INR |
| 销售、一般及管理费用 | 1123.37亿 INR | 938.7亿 INR | 772.01亿 INR | 680.26亿 INR | 620.81亿 INR |
| 营业费用 | 1376.51亿 INR | 1185.85亿 INR | 958.78亿 INR | 821.99亿 INR | 843.64亿 INR |
| 利息收入 | 82.81亿 INR | 26.77亿 INR | 22.78亿 INR | 11.8亿 INR | 9.65亿 INR |
| 利息支出 | 39.33亿 INR | 28.29亿 INR | 17.11亿 INR | 14.28亿 INR | 9.58亿 INR |
| 折旧和摊销 | 216.82亿 INR | 170.58亿 INR | 148.41亿 INR | 126.36亿 INR | 118.24亿 INR |
| 营业利润 | 488.68亿 INR | 718.43亿 INR | 677.29亿 INR | 571.44亿 INR | 294.76亿 INR |
| 净利润 | 450.87亿 INR | 565.44亿 INR | 556.84亿 INR | 450.67亿 INR | 235.68亿 INR |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$14.80
上涨空间 15.44%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年11月5日 | 5:1 | — | — |
股票拆分 | 2006年9月7日 | 2:1 | — | — |
已生效 2024年11月5日
5:1
已生效 2006年9月7日
2:1
报告持有此股票敞口的交易所交易基金。
Alliance Bernstein - AB Emerging Markets Opportunities ETFEMOP4734.56万2.20%21.47亿 USD0.70%US$50.56-0.94%
Vanguard FTSE Emerging Markets ETFVWO2273.14万0.01%1685亿 USD0.06%US$59.73-0.05%
Avantis Emerging Markets Equity ETFAVEM2089.67万0.07%284.09亿 USD0.33%US$93.27-0.89%
State Street SPDR Portfolio Emerging Markets ETFSPEM1809.06万0.10%175.99亿 USD0.07%US$52.12-0.17%
Vanguard Total International Stock ETFVXUS1060.25万0.00%6657亿 USD0.05%US$84.435-0.45%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM477.87万0.05%96.67亿 USD0.39%US$39.67-0.85%
Dimensional - Emerging Core Equity Market ETFDFAE452.86万0.04%101.12亿 USD0.29%US$39.06-0.86%
Vanguard FTSE All-World ex-US ETFVEU428.02万0.00%986亿 USD0.04%US$82.49-0.40%Alliance Bernstein - AB Emerging Markets Opportunities ETFEMOPVanguard FTSE Emerging Markets ETFVWOAvantis Emerging Markets Equity ETFAVEMState Street SPDR Portfolio Emerging Markets ETFSPEMVanguard Total International Stock ETFVXUSDimensional - Emerging Markets Core Equity 2 ETFDFEMDimensional - Emerging Core Equity Market ETFDFAEVanguard FTSE All-World ex-US ETFVEUAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
